Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting.
PARP inhibitor
adverse effects
medication therapy management
multidisciplinary team
ovarian cancer
patient care
quality of life
rucaparib
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
11
2019
accepted:
27
03
2020
entrez:
12
6
2020
pubmed:
12
6
2020
medline:
12
6
2020
Statut:
epublish
Résumé
The use of targeted therapeutics known as poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in the management of ovarian cancer is currently transforming clinical practice. The PARP inhibitor rucaparib is indicated in the UK, European Union and the United States for use in the treatment and maintenance settings for patients with relapsed ovarian cancer. Here, we discuss some of the real-world challenges and side effects that we have encountered while prescribing rucaparib, and we provide practical guidance on how the individual members of our multidisciplinary team (MDT), including a clinician, chemotherapy nurse practitioner, and clinical pharmacist, collaborate to manage these side effects. If recognized early, the side effects experienced by patients during rucaparib therapy, which include fatigue, nausea and vomiting, liver enzyme elevations, and anemia, can be easily managed. For example, providing patients with prophylactic antiemetics can help them avoid nausea, and early detection of decreases in hemoglobin levels allows for proactive interventions to alleviate anemia. The MDT should work together with the patient to identify potential side effects early and manage them effectively. The aim of this proactive approach is to maintain patients on rucaparib for optimal clinical benefit, while minimizing the potential negative impact of side effects on patient quality of life.
Identifiants
pubmed: 32523631
doi: 10.1177/1758835920921980
pii: 10.1177_1758835920921980
pmc: PMC7257860
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1758835920921980Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: Laura Tookman has served on an advisory board for AstraZeneca, has served as a consultant for Tesaro, and has received compensation for travel from Tesaro. Jonathan Krell has served on advisory boards for Clovis Oncology, AstraZeneca, and Tesaro. Baleseng Nkolobe has served on an advisory board for Clovis Oncology and has received honoraria and compensation for travel from Tesaro. Laura Burley declares no competing interests. Iain A. McNeish has served on advisory boards for Clovis Oncology, AstraZeneca, Takeda, and Tesaro and receives institutional funding from AstraZeneca.
Références
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
J Clin Oncol. 2008 Aug 1;26(22):3785-90
pubmed: 18591545
N Engl J Med. 2019 Dec 19;381(25):2403-2415
pubmed: 31562800
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Int J Womens Health. 2013;5:45-51
pubmed: 23378788
N Engl J Med. 2012 Apr 12;366(15):1382-92
pubmed: 22452356
Gynecol Oncol. 2017 Nov;147(2):267-275
pubmed: 28882436
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv96-iv110
pubmed: 29471514
Int J Gynecol Cancer. 2019 Nov;29(9):1396-1404
pubmed: 31685558
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv111-iv125
pubmed: 30016389
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
Mol Cancer Ther. 2007 Mar;6(3):945-56
pubmed: 17363489
Xenobiotica. 2017 Oct;47(10):903-915
pubmed: 27684210
J Clin Oncol. 2019 Sep 20;37(27):2424-2436
pubmed: 31403861
Clin Cancer Res. 2014 Feb 1;20(3):764-75
pubmed: 24240112
Nat Biotechnol. 2012 Feb 19;30(3):283-8
pubmed: 22343925
J Med Genet. 2016 Oct;53(10):655-61
pubmed: 27208206
J Natl Cancer Inst. 2011 Feb 16;103(4):334-46
pubmed: 21183737
Ther Adv Med Oncol. 2017 Aug;9(8):519-531
pubmed: 28794804
Lancet Oncol. 2019 Jan;20(1):e15-e28
pubmed: 30614472
Cancer Metastasis Rev. 2015 Mar;34(1):11-7
pubmed: 25566684
Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32
pubmed: 24078660
Int J Gynecol Cancer. 2020 Jan;30(1):89-93
pubmed: 31792084
J Pharm Sci. 2013 Dec;102(12):4426-32
pubmed: 24122511
J Clin Oncol. 2018 Jan 20;36(3):283-299
pubmed: 29182495
Ann Oncol. 2012 Oct;23(10):2605-12
pubmed: 22910840